SCHEMBL467580

SCHEMBL467580

Nc1nc(N)n(-c2ccc(N3CC4CN(C5CCCC5)CC4C3)c(F)c2)n1

nearest known ligand 0.36

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
AXL P30530 3/20 0.36
INSR P06213 1/20 0.36
KDR P35968 1/20 0.36
HRH4 Q9H3N8 1/20 0.30
KDM1A O60341 2/20 0.30
OPRK1 P41145 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27790975 0.86 AXL (0.47) AXLINSRKDR
SCHEMBL30090809 0.86 AXL (0.47) AXLINSRKDR
SCHEMBL467659 0.82 AXL (0.49) AXLINSRKDR
SCHEMBL27790983 0.82 AXL (0.38) AXLINSRKDR
SCHEMBL467833 0.82 AXL (0.47) AXLINSRKDR
SCHEMBL467688 0.82 AXL (0.40) AXLINSRKDRKDM1A
SCHEMBL467792 0.80 AXL (0.44) AXLINSRKDR
SCHEMBL28784752 0.79 HRH3 (0.39) AXLINSRKDR
SCHEMBL467696 0.77 AXL (0.43) AXLINSRKDR
SCHEMBL467478 0.77 AXL (0.42) AXLINSRKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2387395-A1 AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER Rigel Pharmaceuticals, Inc. (US) 2011-11-23 EP disclosed
US-8040491-B2 Exposure method, substrate stage, exposure apparatus, and device manufacturing method NIKON CORPORATION (JP) 2011-10-18 US disclosed